{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:04:42Z","timestamp":1791389082657,"version":"4.3.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T00:00:00Z","timestamp":1424390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00277-015-2333-z","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T05:50:18Z","timestamp":1424325018000},"page":"547-556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients\u2014an evidence-based approach"],"prefix":"10.1007","volume":"94","author":[{"given":"Meinolf","family":"Karthaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lehrnbecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Lipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Buchheidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,20]]},"reference":[{"issue":"20","key":"2333_CR1","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.2174\/13816128113199990330","volume":"19","author":"M Karthaus","year":"2013","unstructured":"Karthaus M, Buchheidt D (2013) Invasive aspergillosis: new insights into disease, diagnostic and treatment. Curr Pharm Des 19(20):3569\u20133594","journal-title":"Curr Pharm Des"},{"issue":"6","key":"2333_CR2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group (2002) Voriconazole versus amphotericin B forprimarytherapyof invasive aspergillosis. N Engl J Med 347(6):408\u2013415","journal-title":"N Engl J Med"},{"issue":"25","key":"2333_CR3","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1056\/NEJM200212193472518","volume":"347","author":"M Karthaus","year":"2002","unstructured":"Karthaus M (2002) Voriconazole versus amphotericin B for invasive aspergillosis. N Engl J Med 347(25):2080\u20132081","journal-title":"N Engl J Med"},{"key":"2333_CR4","unstructured":"ESCMID guidelines for diagnosis and treatment of Aspergillus diseases. Presented at ECCMID 2014; EW19."},{"issue":"3","key":"2333_CR5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","volume":"46","author":"TJ Walsh","year":"2008","unstructured":"Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of America (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327\u2013360","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2333_CR6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","volume":"46","author":"J Maertens","year":"2011","unstructured":"Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fl\u00fcckiger U, Fr\u00eare P, Gachot B, Heinz WJ, Lass-Fl\u00f6rl C, Ribaud P, Thiebaut A, Cordonnier C (2011) Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20132009 update. Bone Marrow Transplant 46(5):709\u2013718","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"2333_CR7","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1517\/14656566.2013.838217","volume":"14","author":"RH Drew","year":"2013","unstructured":"Drew RH, Townsend ML, Pound MW, Johnson SW, Perfect JR (2013) Recent advances in the treatment of life-threatening, invasive fungal infections. Expert Opin Pharmacother 14(17):2361\u20132374","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 4","key":"2333_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2012.761135","volume":"29","author":"D Andes","year":"2013","unstructured":"Andes D (2013) Optimizing antifungal choice and administration. Curr Med Res Opin 29(Suppl 4):13\u201318","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2333_CR9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2515\/therapie\/2011009","volume":"66","author":"A Hulin","year":"2011","unstructured":"Hulin A, Dailly E, Le Guellec C, Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique (2011) Level of evidence for therapeutic drug monitoring of voriconazole. Therapie 66(2):109\u2013114","journal-title":"Therapie"},{"issue":"3","key":"2333_CR10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10156-013-0607-8","volume":"19","author":"Y Hamada","year":"2013","unstructured":"Hamada Y, Tokimatsu I, Mikamo H, Kimura M, Seki M, Takakura S, Ohmagari N, Takahashi Y, Kasahara K, Matsumoto K, Okada K, Igarashi M, Kobayashi M, Mochizuki T, Nishi Y, Tanigawara Y, Kimura T, Takesue Y (2013) Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 19(3):381\u2013392","journal-title":"J Infect Chemother"},{"issue":"9","key":"2333_CR11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1586\/14787210.2013.826989","volume":"11","author":"S Seyedmousavi","year":"2013","unstructured":"Seyedmousavi S, Mouton JW, Verweij PE, Br\u00fcggemann RJ (2013) Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther 11(9):931\u2013941","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"2333_CR12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/319366","volume":"32","author":"MA Kish","year":"2001","unstructured":"Kish MA (2001) Infectious Diseases Society of America. Guide to development of practice guidelines. Clin Infect Dis 32(6):851\u2013854","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2333_CR13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","volume":"55","author":"WB Park","year":"2012","unstructured":"Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, Oh MD, Yu KS (2012) The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 55(8):1080\u20131087","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2333_CR14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H (2006) Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45(7):649\u2013663","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"2333_CR15","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","volume":"47","author":"D Andes","year":"2003","unstructured":"Andes D, Marchillo K, Stamstad T, Conklin R (2003) In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47(10):3165\u20133169","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2333_CR16","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/jac\/dku023","volume":"69","author":"M Siopi","year":"2014","unstructured":"Siopi M, Mavridou E, Mouton JW, Verweij PE, Zerva L, Meletiadis J (2014) Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic\/pharmacodynamic model. J Antimicrob Chemother 69(6):1611\u20131619","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"2333_CR17","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","volume":"109","author":"S Trifilio","year":"2007","unstructured":"Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J (2007) Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109(8):1532\u20131535","journal-title":"Cancer"},{"issue":"23","key":"2333_CR18","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1056\/NEJMoa1212972","volume":"367","author":"MA Kainer","year":"2012","unstructured":"Kainer MA, Reagan DR, Nguyen DB, Wiese AD, Wise ME, Ward J, Park BJ, Kanago ML, Baumblatt J, Schaefer MK, Berger BE, Marder EP, Min JY, Dunn JR, Smith RM, Dreyzehner J, Jones TF, Tennessee Fungal Meningitis Investigation Team (2012) Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med 367(23):2194\u20132203","journal-title":"N Engl J Med"},{"issue":"8","key":"2333_CR19","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","volume":"46","author":"L Purkins","year":"2002","unstructured":"Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D (2002) Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46(8):2546\u20132553","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2333_CR20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2125.2010.03801.x","volume":"71","author":"S Lee","year":"2011","unstructured":"Lee S, Kim BH, Nam WS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS (2011) Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 71(1):137\u2013138","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"2333_CR21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3109\/00498254.2010.503814","volume":"40","author":"C Eiden","year":"2010","unstructured":"Eiden C, Cociglio M, Hillaire-Buys D, Eymard-Duvernay S, Ceballos P, Fegueux N, Peyri\u00e8re H (2010) Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. Xenobiotica 40(10):701\u2013706","journal-title":"Xenobiotica"},{"issue":"6","key":"2333_CR22","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jac\/dku031","volume":"69","author":"MJ Dolton","year":"2014","unstructured":"Dolton MJ, Mikus G, Weiss J, Ray JE, McLachlan AJ (2014) Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J Antimicrob Chemother 69(6):1633\u20131641","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2333_CR23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2133\/dmpk.DMPK-11-RV-111","volume":"27","author":"K Kurose","year":"2012","unstructured":"Kurose K, Sugiyama E, Saito Y (2012) Population differences in major functional polymorphisms of pharmacokinetics\/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 27(1):9\u201354","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"2333_CR24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0009-9236(96)90129-0","volume":"60","author":"JS Marinac","year":"1996","unstructured":"Marinac JS, Balian JD, Foxworth JW, Willsie SK, Daus JC, Owen R, Flockhart DA (1996) Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 60(2):138\u2013144","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2333_CR25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0b013e31820530cd","volume":"33","author":"A Hassan","year":"2011","unstructured":"Hassan A, Burhenne J, Riedel KD, Weiss J, Mikus G, Haefeli WE, Czock D (2011) Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit 33(1):86\u201393","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2333_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2125.2011.04156.x","volume":"74","author":"MM Malingr\u00e9","year":"2012","unstructured":"Malingr\u00e9 MM, Godschalk PC, Klein SK (2012) A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17\/*17 patient comedicated with carbamazepine. Br J Clin Pharmacol 74(1):205\u2013206","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2333_CR27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/pbc.24262","volume":"60","author":"SH Choi","year":"2013","unstructured":"Choi SH, Lee SY, Hwang JY, Lee SH, Yoo KH, Sung KW, Koo HH, Kim YJ (2013) Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer 60(1):82\u201387","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2333_CR28","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/jac\/dks312","volume":"67","author":"E Koselke","year":"2012","unstructured":"Koselke E, Kraft S, Smith J, Nagel J (2012) Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother 67(12):2957\u20132962","journal-title":"J Antimicrob Chemother"},{"key":"2333_CR29","doi-asserted-by":"crossref","unstructured":"Jeong S, Nguyen PD, Desta Z (2009) Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother 53(2):541\u201351","DOI":"10.1128\/AAC.01123-08"},{"issue":"8","key":"2333_CR30","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/bmt.2009.345","volume":"45","author":"SM Trifilio","year":"2010","unstructured":"Trifilio SM, Scheetz MH, Pi J, Mehta J (2010) Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring. Bone Marrow Transplant 45(8):1352\u20131356","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2333_CR31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dkp464","volume":"65","author":"S Cronin","year":"2010","unstructured":"Cronin S, Chandrasekar PH (2010) Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother 65(3):410\u2013416","journal-title":"J Antimicrob Chemother"},{"key":"2333_CR32","unstructured":"Voriconazole; Summary of product characteristics; EMA January 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000387\/WC500049756.pdf . Accessed 14 Jul 2014"},{"key":"2333_CR33","unstructured":"FDA Antiviral Drugs Advisory Committee Briefing Document for Voricoanzole. FDA 2001. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3792b2_01_pfizer.pdf . Accessed 14 Jul 2014"},{"issue":"3","key":"2333_CR34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","volume":"55","author":"A Pascual","year":"2012","unstructured":"Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O (2012) Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 55(3):381\u2013390","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2333_CR35","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1128\/AAC.44.5.1209-1213.2000","volume":"44","author":"S Perea","year":"2000","unstructured":"Perea S, Pennick GJ, Modak A, Fothergill AW, Sutton DA, Sheehan DJ, Rinaldi MG (2000) Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother 44(5):1209\u20131213","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2333_CR36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1128\/AAC.00901-08","volume":"53","author":"RJ Br\u00fcggemann","year":"2009","unstructured":"Br\u00fcggemann RJ, Touw DJ, Aarnoutse RE, Verweij PE, Burger DM (2009) International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother 53(1):303\u2013305","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2333_CR37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bmt.1704828","volume":"35","author":"S Trifilio","year":"2005","unstructured":"Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, Zembower T, Mehta J (2005) Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 35(5):509\u2013513","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2333_CR38","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1016\/j.ijid.2011.06.004","volume":"15","author":"SH Kim","year":"2011","unstructured":"Kim SH, Yim DS, Choi SM, Kwon JC, Han S, Lee DG, Park C, Kwon EY, Park SH, Choi JH, Yoo JH (2011) Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis 15(11):e753\u2013e758","journal-title":"Int J Infect Dis"},{"issue":"5","key":"2333_CR39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12185-009-0296-3","volume":"89","author":"K Ueda","year":"2009","unstructured":"Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, Kurokawa M (2009) Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 89(5):592\u2013599","journal-title":"Int J Hematol"},{"issue":"7","key":"2333_CR40","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1128\/AAC.00251-13","volume":"57","author":"M Hoenigl","year":"2013","unstructured":"Hoenigl M, Duettmann W, Raggam RB, Seeber K, Troppan K, Fruhwald S, Prueller F, Wagner J, Valentin T, Zollner-Schwetz I, W\u00f6lfler A, Krause R (2013) Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother 57(7):3262\u20133267","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2333_CR41","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1345\/aph.1H671","volume":"41","author":"C Eiden","year":"2007","unstructured":"Eiden C, Peyri\u00e8re H, Cociglio M, Djezzar S, Hansel S, Blayac JP, Hillaire-Buys D, Network of the French Pharmacovigilance Centers (2007) Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 41(5):755\u2013763","journal-title":"Ann Pharmacother"},{"key":"2333_CR42","doi-asserted-by":"crossref","unstructured":"Racil Z, Winterova J, Kouba M, Zak P, Malaskova L, Buresova L, Toskova M, Lengerova M, Kocmanova I, Weinbergerova B, Timilsina S, Rolencova M, Cetkovsky P, Mayer J (2012) Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses 55(6):483\u2013492","DOI":"10.1111\/j.1439-0507.2012.02186.x"},{"key":"2333_CR43","doi-asserted-by":"crossref","unstructured":"Hope WW (2012) Population pharmacokinetics\u00a0of\u00a0voriconazole in adults. AntimicrobAgentsChemother 56(1):526\u2013531","DOI":"10.1128\/AAC.00702-11"},{"issue":"2","key":"2333_CR44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","volume":"46","author":"A Pascual","year":"2008","unstructured":"Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46(2):201\u2013211","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2333_CR45","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jac\/dkr517","volume":"67","author":"P Soler-Palac\u00edn","year":"2012","unstructured":"Soler-Palac\u00edn P, Frick MA, Mart\u00edn-Nalda A, Lanaspa M, Pou L, Rosell\u00f3 E, de Heredia CD, Figueras C (2012) Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother 67(3):700\u2013706","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2333_CR46","first-page":"1","volume":"4","author":"W Heinz","year":"2012","unstructured":"Heinz W, H\u00f6hl R, Karthaus M, Lipp HP, Scherer M (2012) Optimierte therapie invasiver aspergillosen mit voriconazol. Thieme Praxis Report 4(5):1\u201316","journal-title":"Thieme Praxis Report"},{"key":"2333_CR47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cca.2013.05.025","volume":"424","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Tokimatsu I, Sato Y, Kawasaki K, Sato Y, Goto T, Hashinaga K, Itoh H, Hiramatsu K, Kadota J (2013) Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Clin Chim Acta 424:119\u2013122","journal-title":"Clin Chim Acta"},{"issue":"4","key":"2333_CR48","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","volume":"50","author":"J Smith","year":"2006","unstructured":"Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D (2006) Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50(4):1570\u20131572","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2333_CR49","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","volume":"34","author":"DW Denning","year":"2002","unstructured":"Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34(5):563\u2013571","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2333_CR50","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","volume":"56","author":"MJ Dolton","year":"2012","unstructured":"Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ (2012) Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 56(9):4793\u20134799","journal-title":"Antimicrob Agents Chemother"},{"issue":"45\u201346","key":"2333_CR51","first-page":"739","volume":"136","author":"A Imhof","year":"2006","unstructured":"Imhof A, Schaer DJ, Schanz U, Schwarz U (2006) Neurological adverse events voriconazole: evidence fort herapeutic drug monitoring. Swiss Med Wkly 136(45\u201346):739\u2013742","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"2333_CR52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","volume":"50","author":"M Neely","year":"2010","unstructured":"Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J (2010) Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 50(1):27\u201336","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2333_CR53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2133\/dmpk.DMPK-13-NT-007","volume":"28","author":"F Lemaitre","year":"2013","unstructured":"Lemaitre F, Barbaz M, Scailteux LM, Uhel F, Tadi\u00e9 JM, Verdier MC, Bellissant E (2013) A Case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms. Drug Metab Pharmacokinet 28(5):439\u2013441","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"2333_CR54","first-page":"395","volume":"42","author":"HM Lazarus","year":"2002","unstructured":"Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A (2002) Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J ClinPharmacol 42(4):395\u2013402","journal-title":"J ClinPharmacol"},{"issue":"8","key":"2333_CR55","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/AAC.01731-09","volume":"54","author":"C Michael","year":"2010","unstructured":"Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, Mauz-K\u00f6rholz C, Preiss R (2010) Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother 54(8):3225\u20133232","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2333_CR56","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/jac\/dks258","volume":"67","author":"S Pieper","year":"2012","unstructured":"Pieper S, Kolve H, Gumbinger HG, Goletz G, W\u00fcrthwein G, Groll AH (2012) Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother 67(11):2717\u20132724","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2333_CR57","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","volume":"55","author":"PF Troke","year":"2011","unstructured":"Troke PF, Hockey HP, Hope WW (2011) Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 55(10):4782\u20134788","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2333_CR58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.01540-12","volume":"57","author":"IH Bartelink","year":"2013","unstructured":"Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, Boelens JJ, Bierings M (2013) Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother 57(1):235\u2013240","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2333_CR59","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/adc.2007.118844","volume":"93","author":"AC Pasqualotto","year":"2008","unstructured":"Pasqualotto AC, Shah M, Wynn R, Denning DW (2008) Voriconazole plasma monitoring. Arch Dis Child 93(7):578\u2013581","journal-title":"Arch Dis Child"},{"issue":"2","key":"2333_CR60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10096-010-1079-8","volume":"30","author":"I Spriet","year":"2011","unstructured":"Spriet I, Cosaert K, Renard M, Uyttebroeck A, Meyts I, Proesmans M, Meyfroidt G, de Hoon J, Verbesselt R, Willems L (2011) Voriconazole plasma levels in children are highly variable. Eur J Clin Microbiol Infect Dis 30(2):283\u2013287","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"2333_CR61","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.05219-11","volume":"56","author":"D Mitsani","year":"2012","unstructured":"Mitsani D, Nguyen MH, Shields RK, Toyoda Y, Kwak EJ, Silveira FP, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Clancy CJ (2012) Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 56(5):2371\u20132377","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2333_CR62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2334-13-105","volume":"13","author":"HY Chu","year":"2013","unstructured":"Chu HY, Jain R, Xie H, Pottinger P, Fredricks DN (2013) Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis 13(1):105","journal-title":"BMC Infect Dis"},{"issue":"5","key":"2333_CR63","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2009.12.021","volume":"35","author":"P Myrianthefs","year":"2010","unstructured":"Myrianthefs P, Markantonis SL, Evaggelopoulou P, Despotelis S, Evodia E, Panidis D, Baltopoulos G (2010) Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. Int J Antimicrob Agents 35(5):468\u2013472","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"2333_CR64","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","volume":"40","author":"S Trifilio","year":"2007","unstructured":"Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, Winter J, Tallman M, Pi J, Mehta J (2007) Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 40(5):451\u2013456","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2333_CR65","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1128\/AAC.01316-08","volume":"53","author":"SM Trifilio","year":"2009","unstructured":"Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J (2009) Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 53(5):1793\u20131796","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2333-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2333-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2333-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:49:58Z","timestamp":1559036998000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2333-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,20]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2333"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2333-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,20]]}}}